504 related articles for article (PubMed ID: 33555197)
1. Tumor-Associated Macrophages Promote Oxaliplatin Resistance
Lan H; Liu Y; Liu J; Wang X; Guan Z; Du J; Jin K
Mol Pharm; 2021 Mar; 18(3):1026-1037. PubMed ID: 33555197
[TBL] [Abstract][Full Text] [Related]
2. METTL3 facilitates tumor progression via an m
Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
[TBL] [Abstract][Full Text] [Related]
3. TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach.
Cheraghi-Shavi T; Jalal R; Minuchehr Z
PLoS One; 2023; 18(8):e0289535. PubMed ID: 37535601
[TBL] [Abstract][Full Text] [Related]
4. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
Xu R; Yin J; Zhang Y; Zhang S
J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
[TBL] [Abstract][Full Text] [Related]
5. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
[TBL] [Abstract][Full Text] [Related]
6. RNA N
Chen H; Gao S; Liu W; Wong CC; Wu J; Wu J; Liu D; Gou H; Kang W; Zhai J; Li C; Su H; Wang S; Soares F; Han J; He HH; Yu J
Gastroenterology; 2021 Mar; 160(4):1284-1300.e16. PubMed ID: 33217448
[TBL] [Abstract][Full Text] [Related]
7. CPEB3 inhibits epithelial-mesenchymal transition by disrupting the crosstalk between colorectal cancer cells and tumor-associated macrophages via IL-6R/STAT3 signaling.
Zhong Q; Fang Y; Lai Q; Wang S; He C; Li A; Liu S; Yan Q
J Exp Clin Cancer Res; 2020 Jul; 39(1):132. PubMed ID: 32653013
[TBL] [Abstract][Full Text] [Related]
8. METTL3 antagonizes 5‑FU chemotherapy and confers drug resistance in colorectal carcinoma.
Li M; Xia M; Zhang Z; Tan Y; Li E; Guo Z; Fang M; Zhu Y; Hu Z
Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35856434
[TBL] [Abstract][Full Text] [Related]
9. m
Shen C; Xuan B; Yan T; Ma Y; Xu P; Tian X; Zhang X; Cao Y; Ma D; Zhu X; Zhang Y; Fang JY; Chen H; Hong J
Mol Cancer; 2020 Apr; 19(1):72. PubMed ID: 32245489
[TBL] [Abstract][Full Text] [Related]
10. LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling.
Shi CJ; Xue ZH; Zeng WQ; Deng LQ; Pang FX; Zhang FW; Fu WM; Zhang JF
Cancer Gene Ther; 2023 Jun; 30(6):855-865. PubMed ID: 36782047
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis.
Wei C; Yang C; Wang S; Shi D; Zhang C; Lin X; Liu Q; Dou R; Xiong B
Mol Cancer; 2019 Mar; 18(1):64. PubMed ID: 30927925
[TBL] [Abstract][Full Text] [Related]
12. miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4.
Azar MRMH; Aghazadeh H; Mohammed HN; Sara MRS; Hosseini A; Shomali N; Tamjidifar R; Tarzi S; Mansouri M; Sarand SP; Marofi F; Akbari M; Xu H; Shotorbani SS
Int Immunopharmacol; 2021 Mar; 92():107355. PubMed ID: 33429333
[TBL] [Abstract][Full Text] [Related]
13. Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells.
Park J; Lee GE; An HJ; Lee CJ; Cho ES; Kang HC; Lee JY; Lee HS; Choi JS; Kim DJ; Choi JS; Cho YY
Arch Pharm Res; 2021 Dec; 44(12):1091-1108. PubMed ID: 34750753
[TBL] [Abstract][Full Text] [Related]
14. KIF18b-dependent hypomethylation of PARPBP gene promoter enhances oxaliplatin resistance in colorectal cancer.
Hong B; Lu R; Lou W; Bao Y; Qiao L; Hu Y; Liu K; Chen J; Bao D; Ye M; Fang Z; Gong C; Zhang X
Exp Cell Res; 2021 Oct; 407(2):112827. PubMed ID: 34508743
[TBL] [Abstract][Full Text] [Related]
15. m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation.
Xu J; Chen Q; Tian K; Liang R; Chen T; Gong A; Mathy NW; Yu T; Chen X
Oncol Rep; 2020 Sep; 44(3):973-986. PubMed ID: 32705223
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-29b-3p promotes 5-fluorouracil resistance via suppressing TRAF5-mediated necroptosis in human colorectal cancer.
Wu S; Zhou Y; Liu P; Zhang H; Wang W; Fang Y; Shen X
Eur J Histochem; 2021 Jun; 65(2):. PubMed ID: 34155879
[TBL] [Abstract][Full Text] [Related]
17. Novel exosomal miR-46146 transfer oxaliplatin chemoresistance in colorectal cancer.
Xu Y; Zhu M
Clin Transl Oncol; 2020 Jul; 22(7):1105-1116. PubMed ID: 31728833
[TBL] [Abstract][Full Text] [Related]
18. Regulation of ATP-binding cassette subfamily B member 1 by Snail contributes to chemoresistance in colorectal cancer.
Wang H; Li JM; Wei W; Yang R; Chen D; Ma XD; Jiang GM; Wang BL
Cancer Sci; 2020 Jan; 111(1):84-97. PubMed ID: 31774615
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer.
Min AKT; Mimura K; Nakajima S; Okayama H; Saito K; Sakamoto W; Fujita S; Endo H; Saito M; Saze Z; Momma T; Ohki S; Kono K
Cancer Immunol Immunother; 2021 Feb; 70(2):289-298. PubMed ID: 32705303
[TBL] [Abstract][Full Text] [Related]
20. N
Zhang K; Zhang T; Yang Y; Tu W; Huang H; Wang Y; Chen Y; Pan K; Chen Z
Theranostics; 2022; 12(10):4802-4817. PubMed ID: 35832094
[No Abstract] [Full Text] [Related]
[Next] [New Search]
